Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 3/20 | 0.35 |
| ▸ | MTOR | P42345 | 3/20 | 0.31 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1947412 | 0.96 | F9 (0.33) | F9TRPV1 | |
| SCHEMBL1949008 | 0.85 | MAPK14 (0.32) | TRPV1 | |
| Ammonia Solution, Strong SCHEMBL1950693 | 0.82 | F9 (0.51) | F9MTORAKT1TRPV1PIK3CD | |
| SCHEMBL1950224 | 0.81 | F9 (0.41) | F9MTORAKT1TRPV1PIK3CD | |
| SCHEMBL15103415 | 0.79 | F9 (0.41) | F9MTORAKT1TRPV1PIK3CD | |
| Ammonia Solution, Strong SCHEMBL1445030 | 0.78 | F9 (0.48) | F9TRPV1 | |
| SCHEMBL1947802 | 0.77 | F9 (0.39) | F9TRPV1 | |
| SCHEMBL15103680 | 0.75 | F9 (0.39) | F9MTORAKT1TRPV1TYRO3 | |
| SCHEMBL1947056 | 0.67 | MAPK1 (0.33) | TRPV1 | |
| Ammonia Solution, Strong SCHEMBL1949006 | 0.66 | F9 (0.46) | F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F9 2/4885MTOR 2535/4885AKT1 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.